A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab.

ABSTRACT:

Background

This study sought to explore the biological significance of genetic variation in RAS wild-type metastatic colorectal cancer (mCRC) in the real world, the difference in the efficacy of cetuximab in the treatment of mCRC with different genetic variants and identify clinical features and new predictors of efficacy.

Methods

A retrospective analysis of the data of 60 patients with stage IV mCRC who received cetuximab at The First and Second Affiliated Hospital of Soochow University from 2016 to 2020 was conducted. The patients were divided into the following 3 groups according to the genetic test results: (I) group A (the all-RAS wild-type group); (II) group B (the all-RAS wild-type group with the tumor suppressor gene mutation); and (III) group C

SUBMITTER: Tao H 

PROVIDER: S-EPMC9830345 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature